2025³â 04¿ù 26ÀÏ Åä¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Business

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Galderma to Present New Findings From Innovative Product Portfolio at the 2022 VCS Annual Symposium

´º½ºÀÏÀÚ: 2022-06-08

FORT WORTH, TEXAS-- June 08, 2022 -- Galderma, the leading company solely dedicated to advancing the future of dermatology, announced it will present four scientific presentations at the 2022 Vegas Cosmetic Surgery (VCS) & Aesthetic Dermatology Annual Symposium to showcase the latest advancements surrounding its approved and investigational product updates.

“We look forward to unveiling the latest data and research across our innovative dermatology pipeline and portfolio at this year’s VCS symposium,” said Bill Andriopoulos, Vice President, Medical Affairs Galderma U.S. “Our commitment to patients is underscored by the dermatological solutions we are investigating and bringing to market. We are excited to continue to realize the potential of our product portfolio and share our findings with the larger scientific community.”

The data presentations stem from Galderma’s neuromodulators relabotulinumtoxinA (QM1114), an investigational product, and Dysport® (abobotulinumtoxinA)* as well as its collagen stimulator, Sculptra® (injectable poly-L-lactic acid).

There will be two scientific presentations featuring the latest READY-1 and READY-2 Phase 3 data of relabotulinumtoxinA, a proprietary novel, ready-to-use, liquid formulation of investigational botulinum toxin, for the treatment of glabellar lines and lateral canthal lines. There will also be data presented from across three individual trials investigating the subject-relevant outcomes of on-label 50U Dysport for the treatment for moderate-to-severe glabellar lines. Additionally, data from NCT03780244, an open-label extension study to evaluate the safety and effectiveness of Sculptra after changes in reconstitution and injection procedure, will be presented at the symposium.



 Àüü´º½º¸ñ·ÏÀ¸·Î

LG Releases Preliminary Earnings for First-Quarter 2025
NIQ Unveils Consumer Tech Industry Trends 2025 Report: Global Sales to Hit $1.29T
Novotech Welcomes New Investment From GIC, Temasek, and Existing Investor TPG to Accelerate Global Growth
NIQ Signs Definitive Agreement to Acquire Gastrograph AI Further Enhancing CPG Innovation Through AI-Driven Data, Platforms, and Capabilities
LG 2025 OLED Earns Eco-Certifications for Sustainable Design and Reduced Carbon Footprint
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta¢ç (pertuzumab) Biosimilar Candidate HLX11
Former DOT Deputy General Counsel Brian Stansbury Joins Hunton¡¯s Environmental Team in Washington

 

Merz Aesthetics¢ç Announced Salma Hayek Pinault as First-Ever Global B...
AppsFlyer and NAVER Announce Audience Integration to Enhance Digital M...
Gradiant Wins Gold at Edison Awards 2025 for ForeverGone PFAS Removal ...
Natus Sensory Strengthens Executive Team with Key Leadership Appointme...
Perma-Pipe International Holdings, Inc., announces new project awards ...
Rimini Street Honored with Multiple Awards in Recognition of its Custo...
Five Cargill Innovations Win 2025 Edison Awards¢â for Transforming the...

 


°øÁö»çÇ×
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备: ä¹联êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..